Jokhang
2021-07-22
[Surprised]
[Surprised]
[Surprised]
[Surprised]
How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":172662029,"tweetId":"172662029","gmtCreate":1626959496861,"gmtModify":1633769384570,"author":{"id":3586392338558856,"idStr":"3586392338558856","authorId":3586392338558856,"authorIdStr":"3586392338558856","name":"Jokhang","avatar":"https://static.tigerbbs.com/d189ae3ec01747be0bd951c14c32cb94","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Surprised] </span><span>[Surprised] </span><span>[Surprised] </span><span>[Surprised] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Surprised] </span><span>[Surprised] </span><span>[Surprised] </span><span>[Surprised] </span><br></p></body></html>","text":"[Surprised] [Surprised] [Surprised] [Surprised]","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/172662029","repostId":2153678132,"repostType":4,"repost":{"id":"2153678132","kind":"highlight","pubTimestamp":1626958620,"share":"https://www.laohu8.com/m/news/2153678132?lang=&edition=full","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8 <a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":200,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":44,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/172662029"}
精彩评论